INTRODUCTION
============

Animal models are indispensable in studying the mechanisms responsible for the pathogenesis and complications of type 2 diabetes (T2D), as well as preclinical testing for novel therapeutic agents. Early attempts to establish a hyperglycemic phenotype utilized experimental destruction of the pancreas, accomplished either surgically or chemically (e.g. streptozotocin, alloxan). Although both methods continue to be used, they are often criticized as not accurately reflecting the human T2D phenotype. Moreover, the induction of diabetes can be variable and labor intensive, as in the case of partial pancreatectomy. Thus, many investigators rely on specific rodent strains that model key features of T2D. These genetic models have been widely used to explore the pathophysiology of obesity and T2D, as well as in preclinical drug development.

Genetic rodent models can recapitulate several phenotypes of human T2D, including fasting hyperglycemia, increased rates of glucose production and increased gluconeogenesis. However, the underlying mechanisms for these changes could be very different. We recently reported that fasting hyperglycemia in Zucker diabetic fatty (ZDF)-\[*Lepr^fa^*\] rats and *db/db*-\[*Lepr^db^*\] mice was associated with increased hepatic expression of phosphoenolpyruvate carboxykinase (PEPCK), a key gluconeogenic enzyme. In contrast, increased expression of PEPCK was not evident in other rodent models (e.g. streptozotocin-treated high-fat-fed rats) or in individuals with T2D ([@b22-0050681]). One reason for this discrepancy is that many of the inbred T2D rodent strains also have elevated corticosterone, which can increase expression of gluconeogenic enzymes. T2D in humans is not associated with elevations in glucocorticoids ([@b28-0050681]; [@b19-0050681]). Thus, although these common rodent models grossly manifest a similar phenotype as humans with T2D, the underlying mechanisms leading to that phenotype are markedly different.

Although less commonly utilized, the Goto-Kakizaki (GK) rat is also an established model of T2D. This rat strain was developed by selectively breeding Wistar rats for glucose intolerance over multiple generations ([@b7-0050681]; [@b6-0050681]). The resulting animals are a polygenic strain and spontaneously develop hyperglycemia, have decreased β-cell function and manifest several complications of diabetes ([@b14-0050681]; [@b29-0050681]; [@b15-0050681]; [@b10-0050681]). Fasting hyperglycemia in the GK rats is due to increased gluconeogenesis ([@b23-0050681]). However, there are no data regarding corticosterone production in these animals. Here, we determine whether increased corticosterone is associated with hyperglycemia in the GK rat.

RESULTS
=======

GK rats had lower body weights than age-matched Wistar-Kyoto (WK) rats ([Table 1](#t1-0050681){ref-type="table"}). As expected, the GK rats had increased fasting plasma glucose concentrations and rate of endogenous glucose production ([Fig. 1A,B](#f1-0050681){ref-type="fig"}). Hyperglycemia was associated with an ∼twofold increase in fasting plasma insulin concentrations, suggesting insulin resistance. In contrast, fasting plasma glucagon concentrations were equivalent between the two rat strains ([Table 1](#t1-0050681){ref-type="table"}). mRNA expression of key gluconeogenic enzymes \[cytosolic PEPCK (PEPCK1); glucose 6-phosphatase, catalytic (G6Pc) and T-1 translocase (G6Pt); and pyruvate carboxylase (PC)\] were measured ([Fig. 1C--F](#f1-0050681){ref-type="fig"}). PEPCK1 expression was increased twofold in GK rats (*P*=0.02). There was no difference in G6Pt expression between the two groups ([Fig. 1D](#f1-0050681){ref-type="fig"}). In contrast, G6Pc and PC expression were decreased in the GK rats relative to the WK controls.

###### 

Baseline metabolic parameters

![](DMM009035T1)

Increased corticosterone has been documented in other rodent models of T2D. To determine whether or not hypercorticosteronemia plays a role in the phenotype of GK rats, we measured plasma and urinary corticosterone concentrations. Plasma corticosterone was measured after an overnight fast from rodents with indwelling catheters. Plasma corticosterone was elevated approximately threefold ([Fig. 1G](#f1-0050681){ref-type="fig"}). There was no detectable difference in plasma adrenocorticotropic hormone (ACTH) concentrations (WK: 29.0±6.2 ng/ml vs GK: 30.1±6.3 ng/ml, *P*=0.90). Because a single time point might not accurately reflect the entire exposure of the animal to corticosterone, we also measured 24-hour urinary corticosterone excretion, normalized to urinary creatinine. Urinary corticosterone excretion was ∼eightfold higher in the GK rats in comparison with the WK rats ([Fig. 1H](#f1-0050681){ref-type="fig"}). Finally, corticosterone might be regenerated through the action of the 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1). However, neither hepatic nor adipose *11βHSD1* mRNA expression differed between WK and GK rats \[liver WK: 0.57±0.11 relative abundance (RA) vs liver GK: 0.81±0.26 RA, *P*=0.55; white adipose tissue (WAT) WK: 0.57±0.22 RA vs GK: 0.88±0.13 RA, *P*=0.32\].

To determine whether decreasing the corticosterone levels would correct the phenotype, GK rats were treated with ketoconazole (KTZ), a piperazine antifungal agent that inhibits 11β-hydroxylase ([@b12-0050681]). GK rats were gavaged either with KTZ (175 mg/kg body weight) or water for 3 days, followed by a 6-hour fast on the morning of the study. Body weight was unaltered (GK-Water: 266±8 g vs GK-KTZ: 276±7 g). KTZ treatment lowered plasma corticosterone ([Fig. 2A](#f2-0050681){ref-type="fig"}). This was associated with an ∼40% reduction in plasma glucose concentration ([Fig. 2B](#f2-0050681){ref-type="fig"}) and a 25% reduction in the basal rate of glucose production ([Fig. 2C](#f2-0050681){ref-type="fig"}). KTZ treatment reduced plasma insulin concentration (GK-Water: 84.06±7.55 μU/ml vs GK-KTZ: 31.04±6.51 μU/ml, *P*=0.0003) without any change in plasma glucagon concentration (GK-Water: 65.7±11.3 ng/ml vs GK-KTZ: 109.4±21.5 ng/ml, *P*=0.12), suggesting an improvement in insulin sensitivity. These changes were associated with reductions in *PEPCK1* mRNA and protein ([Fig. 2E,F](#f2-0050681){ref-type="fig"}). *PC* mRNA was also reduced (GK-Water: 2.2±0.3 RA vs GK-KTZ: 0.8±0.2 RA, *P*=0.004), but not G6Pc (*P*=0.06) or G6Pt (*P*=0.10). Previous studies in these rats suggested that increased Cori cycling (glucose-alanine cycle) might also be a determinant of increased glucose production. Alanine turnover was decreased ∼20% in GT-KTZ rats ([Fig. 2D](#f2-0050681){ref-type="fig"}), and might represent another mechanism for the reduction in glucose production following KTZ treatment in these animals.

![**Comparison between WK and GK rats after an overnight fast.** (A) Fasting plasma glucose concentration. (B) Endogenous glucose production. (C--F) Expression of gluconeogenic enzymes. (G) Fasting plasma corticosterone. (H) 24-hour urine corticosterone normalized to creatinine. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001. *n*=7--10/group.](DMM009035F1){#f1-0050681}

DISCUSSION
==========

Rodent models are essential for exploring the mechanisms underlying the pathogenesis of T2D and for preclinical testing of novel therapies. Although increased corticosterone has been described in these models ([@b20-0050681]; [@b24-0050681]; [@b25-0050681]; [@b1-0050681]), this remains an underappreciated confounder. Disrupting the increased corticosterone production in these models can ameliorate the phenotype in these strains, either by adrenalectomy ([@b20-0050681]), inhibition of 11βHSD1 ([@b26-0050681]) or knockdown of the glucocorticoid receptor ([@b30-0050681]). The GK rat model differs from these more common models in several aspects. This non-obese strain is thought to have polygenic diabetes ([@b4-0050681]; [@b5-0050681]). The exact genetic defects remain unclear, although linkage studies have identified a region of chromosome 1 that contains genes for *UCP2*, *UCP3* and *Tub* ([@b11-0050681]). GK rats are not known to have mutations in leptin or the leptin receptor genes; one study has reported that these animals do seem to have some degree of leptin resistance ([@b13-0050681]).

![**Effect of KTZ treatment in GK rats.** KTZ treatment in GK rats reduces (A) fasting plasma corticosterone, (B) fasting plasma glucose, (C) rate of endogenous glucose production, (D) rate of alanine turnover, (E) *PEPCK1* mRNA expression and (F) PEPCK1 protein expression in cytosolic fraction (representative blots shown below). \**P*\<0.05, \*\**P*\<0.01. *n*=5--7/group.](DMM009035F2){#f2-0050681}

To ascertain whether the increased corticosterone contributes to the diabetic phenotype in this model, we performed a set of metabolic measurements in GK rats in comparison with WK control rats. We confirmed previous findings demonstrating that GK rats had increased fasting glucose and increased rates of glucose production ([@b3-0050681]; [@b16-0050681]). Recently, studies utilizing a combination of U-^13^C glucose and ^2^H~2~O to quantify the pathways contributing to glucose production demonstrated that GK rats have increased rates of gluconeogenesis that are largely attributable to increased gluconeogenesis from phosphoenolpyruvate, consistent with our finding of increased PEPCK1 expression ([@b23-0050681]). In addition, this study reported an increased contribution of the Cori cycle to glucose production.

In the present study, we found an increased rate of glucose production in GK rats compared with WK rats, and this was associated with increased expression of *PEPCK1* mRNA. In contrast, the expression of other gluconeogenic enzymes was not significantly different. Hypercorticosteronemia per se might account for many of these findings because the promoter elements of the genes encoding these enzymes contain glucocorticoid receptor elements ([@b9-0050681]; [@b8-0050681]; [@b27-0050681]). We observed increases in both fasting plasma corticosterone concentration and 24-hour urinary corticosterone excretion in the GK rat, relative to the WK rat. The increase in plasma corticosterone concentration seemed to be independent of changes in hepatic or adipose *11βHSD1* mRNA expression. Fasting plasma ACTH concentrations were identical, which could suggest that the hypothalamic-pituitary-adrenal axis might have an altered set point for cortisol production, although this is difficult to judge accurately with a single time point.

We further examined the role of corticosterone in the development of the hyperglycemic phenotype in GK rats using KTZ to decrease corticosterone synthesis. Treatment with KTZ decreased plasma corticosterone concentration, and lowered fasting plasma glucose and insulin concentrations. This was associated with a reduction in the basal rate of glucose production and a decrease in the expression of PEPCK1. However, the ability of this enzyme to regulate gluconeogenic flux is much less than previously thought, with a metabolic control coefficient of 0.18, a low value for a 'rate-controlling' enzyme ([@b2-0050681]). Although we also observed a reduction in hepatic *PC* mRNA, there might be other mechanisms accounting for decreased fasting glucose following KTZ. Sena et al. reported that Cori cycle flux was ∼twofold higher in the GK rats compared with WK rats ([@b23-0050681]). Thus, the increased delivery of alanine to the livers of GK rats might contribute to increased gluconeogenesis. Here, we demonstrate that KTZ treatment reduced alanine turnover, suggesting that a decrease in Cori cycling with KTZ treatment might also contribute to the reduction in glucose production.

The present study has some limitations. Suppressing corticosterone production, even in normal rodents, could decrease glucose production. Additionally, the selective inbreeding of the GK rats might have created a strain that has sufficient genetic differences from the WK rat such that a direct comparison is not ideal. Despite this concern, the WK rats remain the best comparator group for these studies. Taken together, these data suggest that increased corticosterone might play a role in the development of the hyperglycemic phenotype in the GK rat by both increasing the gluconeogenic capacity of the liver as well as enhancing substrate delivery. Future studies should examine the underlying mechanisms leading to increased corticosterone in this strain.

There is evidence that tissue-specific production of cortisol contributes to the various features of the metabolic syndrome, for example, through the 11βHSD1 pathway. However, a frank increase in plasma glucocorticoid concentration is not a typical feature in humans with T2D ([@b28-0050681]; [@b19-0050681]). Thus, the increased corticosterone that is present in several rodent models might lead to erroneous conclusions about the pathophysiology of T2D and efficacy of treatments tested in preclinical models. For example, increased gluconeogenesis in these models had been largely ascribed to increased expression of PEPCK, leading to the view that this was a mechanism for increased gluconeogenesis in humans with T2D. However, no relationship between PEPCK and glucose production was seen in models without increased corticosterone or in humans with T2D ([@b22-0050681]). Thus, although the 'ideal' rodent models of T2D will probably remain elusive, corticosterone should be assessed as a potential confounder.

METHODS
=======

Animals
-------

Male GK rats, and male Wistar Kyoto rats, a rodent control model, were obtained from Taconic at approximately 14- to 16-weeks of age. Rats were fed ad libitum the standard commercial diet (NIH \#31M Rodent Diet, Taconic) along with ad libitum access to water. They were housed in 12 hours of light/12 hours of dark cycles and acclimated for 5--7 days prior to the placement of jugular venous and carotid catheters. All studies were approved by the International Animal Care and Use Committee (IACUC) at the Veterans Affairs Medical Center, West Haven, CT.

KTZ treatment
-------------

GK rats received either a dose of water or KTZ suspension (175 mg/kg body weight) via oral gavage technique for 3 consecutive days prior to the experiment. Rats were studied after a 6-hour fast.

Measurement of basal rates of glucose production
------------------------------------------------

Endogenous glucose production was measured in catheterized rats that received unprimed, continuous infusions of 6,6-^2^H glucose for 240 minutes at a rate of 0.025 ml/(kg-minute). In studies measuring alanine turnover, 3-^13^C alanine was infused at 0.5 mg/(kg-minute). Plasma blood samples were obtained at 10-minute intervals between 210 and 240 minutes. At the end of the infusion, rats were euthanized and liver tissues were harvested in situ with tongs that had been pre-cooled in liquid nitrogen.

Metabolites and hormones
------------------------

Blood was collected from surgically placed catheters, as described previously ([@b21-0050681]), after 120 minutes and immediately centrifuged in aprotinized Beckman P100 tubes, and plasma supernatants were removed and stored at 4°C. Plasma glucose was measured by the glucose oxidase method on a Beckman Glucose Analyzer II. Plasma insulin, glucagon and corticosterone were measured by RIA (Millipore). Urine was collected in metabolic cages after allowing for a 24-hour acclimation period. Plasma ACTH was measured by EIA (Phoenix Pharmaceuticals).

Analysis of plasma glucose and alanine by GC/MS
-----------------------------------------------

To determine the enrichment of 6,6-^2^H glucose or alanine in plasma, samples were deproteinized with 5 volumes of 100% methanol, dried, and derivatized with 1:1 acetic anhydride/pyridine to produce the pentacetate derivative of glucose, or with 1:8 trifluoroacetic anhydride/methylene chloride to produce the trifluoroacetyl *n*-butyl ester of alanine. The atom percent of enrichment of glucose~M+2~ and alanine~M+1~ was measured by gas-chromatography--mass-spectrometry (GC/MS) analysis using a Hewlett-Packard 5890 gas chromatograph interfaced to a Hewlett-Packard 5971A mass-selective detector operating in the electron-ionization mode ([@b17-0050681]). Glucose~M+2~ enrichments were determined from the ratio of *m*/*z* 202 to 200. Alanine~M+1~ enrichments were determined from the ratio of *m*/*z* 243 to 242. Endogenous glucose and alanine production was calculated using Steele's equation in steady state ([@b31-0050681]).

###### TRANSLATIONAL IMPACT

**Clinical issue**

A key finding in humans with type 2 diabetes (T2D) is fasting hyperglycemia attributed to increased hepatic gluconeogenesis. Many different rodent models are used to explore the potential mechanism for this clinical phenotype, but the pathogenesis of fasting hyperglycemia in certain models might not be relevant to the human situation. For example, many rodent strains have increased levels of corticosterone, which increases the expression of gluconeogenic enzymes; however, T2D in humans is not associated with increased levels of corticosterone. Although data concerning corticosterone levels were available for several other rodent models, published data were not available for the Goto-Kakizaki (GK) rat, a non-obese rat strain that develops T2D early in life and is an established model of the human disease.

**Results**

These results show that GK rats have increased levels of corticosterone compared with Wistar-Kyoto (WK) control rats. Decreasing plasma corticosterone in GK rats using ketoconazole normalized plasma glucose, decreased endogenous glucose production and seemed to improve insulin sensitivity. This could be attributed to decreased expression of phosphoenolpyruvate carboxykinase (PEPCK; a key gluconeogenic enzyme) and/or decreased Cori cycling.

**Implications and future directions**

These results show that hypercorticosteronemia is associated with hyperglycemia in the GK rat. Given that hypercorticosteronemia is an important confounder in rodent models of T2D, studies involving this model should take this into consideration when investigating mechanisms of T2D and testing responses to therapeutic agents.

Total RNA preparation and real-time quantitative RT-PCR analysis
----------------------------------------------------------------

Total RNA was extracted from liver samples stored in RNAlater solution by using the RNeasy kit (Qiagen). RNA was reverse-transcribed into cDNA by using Stratascript Reverse Transcriptase (Stratagene). The abundance of transcripts for *PEPCK1* (cytosolic), *G6Pc* and *PC* were assessed by real-time PCR using a SYBR Green detection system (Stratagene). For each run, samples were run in duplicate for both the gene of interest and actin. The expression data for each gene of interest and actin were normalized for the efficiency of amplification, as determined by a standard curve included on each run ([@b18-0050681]). All mRNA expression values are expressed as relative abundance (RA).

Assessment of protein content
-----------------------------

Liver proteins were extracted in homogenization buffer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 2 mM Na~3~VO~4~, 20 mM Na~4~P~2~O~7~, 100 mM NaF, 1% Triton X-100, 2 mM PMSF, 20 μg/ml aprotinin, 1 mg/ml leupeptin and pepstatin) and separated into cytosolic and nuclear/mitochondrial fractions via ultracentrifugation. Protein concentrations were determined by the Bradford method (Bio-Rad). Equal amounts of protein were resolved by SDS-PAGE and electroblotted onto a polyvinylidene difluoride membrane (DuPont) by using a semidry transfer cell (Bio-Rad). After blocking for 2 hours at room temperature in TBST containing 5% (wt/vol) non-fat dried milk, and then incubated overnight with polyclonal rabbit anti-PEPCK antibody (SantaCruz). After further washings, membranes were incubated with horseradish-peroxidase-conjugated secondary antibody and visualized by ECL (Amersham). These blots were stripped and reblotted with both HSP90 and VDAC antibody to ensure proper fractionation had occurred.

Statistical analysis
--------------------

Statistical analysis of the data was performed using GraphPad Prism 5.0. All data are expressed as mean ± s.e.m. For comparisons of two groups, Student's *t*-test was used.

We graciously acknowledge the technical assistance of Yanna Kosover and Aida Grossman.

**COMPETING INTERESTS**

The authors declare that they do not have any competing or financial interests.

**AUTHOR CONTRIBUTIONS**

Both authors designed and performed experiments, analyzed data, and wrote and edited the manuscript.

**FUNDING**

This project was supported by a VA Merit Review Award (to V.T.S.).
